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Although concerns of radiation sensitization have been raised with concurrent trastuzumab (Herceptin) administration,
there has been no published case of radiation recall reaction associated with trastuzumab. This case describes a clinical
presentation consistent with a radiation recall reaction following administration of adjuvant trastuzumab after neoadjuvant FEC-
D chemotherapy and locoregional radiotherapy for HER2-positive, locally advanced breast cancer in a premenopausal woman.
Although the mechanism and etiology of radiation recall dermatitis remain unclear, this case raises further hypotheses regarding
a possible drug dose-dependence and possible predisposing risk factor for the development of radiation recall reactions.
Copyright © 2009 Caroline Chung et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. Presentationof Case
A 41-year-old premenopausal woman presented with slight
discomfort in the left breast and a large palpable mass
tetheredtotheunderlyingmuscleintheleftbreastalongwith
a small palpable node in the left axilla. Mammographically,
a5× 5cm mass was noted in the upper outer quadrant of
the left breast. Her previous mammogram a year ago was
negative. The ﬁne needle aspirate of the breast mass was
positive for grade 3 invasive ductal carcinoma, which was
ER negative, PR negative, and Her2/neu ampliﬁed on FISH
analysis.Hermetastaticworkup,includingaliverultrasound
and bone scan, was negative. She was therefore clinically
staged as T3N1MX [1].
Her previous medical history included eczema, allergic
rhinitis, and contact dermatitis to numerous allergens,
including latex. She was otherwise well. Her only previous
surgeries were tubal ligation and tonsillectomy. Her breast
cancer speciﬁc history included menarche at age 11 with
long-term oral contraceptive use from age 12 to 26 for
menstrual regulation. She was nulliparous. Her menses
stopped shortly after starting chemotherapy but restarted in
April 2006. Her family history was unavailable as she was
adopted and did not have information about her biological
parents.
Given her presentation with locally advanced breast
cancer, she received neoadjuvant FEC-D chemotherapy,
consisting of 3 cycles of 5-ﬂuorouracil, epirubicin, and
cyclophosphamide then 3 cycles of docetaxel. She had a
clinical complete response after her ﬁrst cycle of FEC. She
tolerated all 3 cycles of FEC reasonably well. However, after
her ﬁrst cycle of docetaxel, she developed a severe peripheral
neuropathy with signiﬁcant weakness and neuropathic pain
in her upper and lower extremities such that she was unable
to walk for about a week. This was more severe on the left
side than the right. As a result, the subsequent 2 cycles of
docetaxel were reduced in dose by 50%.
Following completion of chemotherapy, she received
locoregional radiotherapy directed to the breast, internal
mammary chain (IMC) lymph nodes, and axilla. She was
treated with CT planned 4-ﬁeld radiotherapy using wide
tangents to encompass the left breast and IMC lymph nodes
alongwithanteriorandposterioraxillaryﬁeldstoencompass
the axillary nodal regions (axillary levels I, II, and III nodal
regions and the supraclavicular and infraclavicular nodal
regions). The whole left breast received 4250cGy in 16 frac-
tions delivered by photons followed by a boost of radiation
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a margin, delivered by electrons. The locoregional lymph
nodes received 3750cGy in 16 fractions.
During the course of radiotherapy, she developed brisk
skin erythema throughout the breast with moist desquama-
tion in the inframammary breast fold, requiring both topical
betamethasone and ﬂamazine cream. The skin healed grad-
ually over the month following completion of radiotherapy.
She was oﬀered left breast upper outer quadrantectomy and
axillary lymph node dissection following her recovery from
radiotherapy, which she declined.
Several weeks after completing radiotherapy but prior
to starting trastuzumab, she developed a severe constant
squeezing left-sided chest pain, which lasted about an hour.
This developed while at rest in bed, and it was so severe
that she was bed-ridden for the entire episode, but the pain
subsided spontaneously without any intervention. She went
for an ECG, bloodwork, and chest x-ray within the next
few days, which were all normal. However, she continued to
notice a vague heavy sensation in her chest, which limited
her activity, particularly walking up stairs. There was no
associated shortness of breath or cough.
She agreed to proceed with trastuzumab therapy starting
4 weeks after completing radiotherapy for a total of 17
cycles.Shecompletedelevendosesoftrastuzumab513.28mg
intravenously in the right (contralateral) arm with which
she was experiencing subtle, intermittent left chest wall
discomfort, not interfering with her daily activities. As she
was concerned about the potential long-term toxicities of
repeat Trastuzumab given in one arm, she requested the 12th
cycle be given via the left (ipsilateral) arm.
Three days after receiving trastuzumab in her ipsilateral
arm, she awoke with a painful, swollen, and erythematous
left breast, axilla and medial left upper arm, which resembled
her previous radiation dermatitis reaction. The erythema-
tous region of the skin was very well demarcated, resembling
theareaofirradiatedskinwithsharplinearbordersfollowing
the borders of her previous radiation ﬁelds. The brisk
erythema largely resolved spontaneously within 2 days, but
the edema and dull, throbbing ache in the breast and
chestwallpersistedforabout2weeks.Asthisoccurredduring
the weekend, she did not seek medical attention immediately
and was seen by the medical oncologist a few days after the
skin reaction had subsided.
At the time of assessment by Radiation Oncology, about
2 weeks after the initial recall reaction, nearly a year since
completing her radiotherapy, she had 2 areas of persistent
tenderness: one in the left inframammary fold and the other
in a more inferior lateral rib. These 2 areas had initially
become tender during her radiotherapy treatment and then
had settled. Subsequently, she had intermittent, exacerba-
tions of discomfort in these areas during her trastuzumab
treatment, but the pain was not as severe as during the
“radiation recall” reaction. At the time of assessment, these
areas were only mildly tender. A bone scan investigating the
rib pain did not show any uptake representing malignancy or
trauma.
Despite the recall reaction, she continued with the
planned doses of trastuzumab, 513.28mg intravenously
via the right (contralateral) arm every three weeks, until
completion of all 17 cycles. She did not receive any pre-
medication with steroids or antihistamines. She completed
the remainder of the cycles without any further episodes of
radiation recall dermatitis, but she continued to experience
vague, intermittent left chestwall discomfort, as she had
noted prior to the recall reaction.
2. Discussion
Over-expression of human epidermal growth factor receptor
type 2 (HER2) is seen in 20%–30% of invasive breast
carcinomas. Trastuzumab is a recombinant monoclonal
antibody with the capability of binding to two antigen-
speciﬁc sites on the HER2 receptor, which in turn is thought
to prevent activation of the intracellular tyrosine kinase
domain. HER2 downstream signaling is believed to promote
cellular proliferation and inhibit cell death [2]. However,
mechanisms that may result in trastuzumab-related toxicity
are not fully understood.
There have been several large randomized studies
demonstrating improvement in overall survival and disease
control with adjuvant trastuzumab after primary breast can-
certherapy(surgery,adjuvantorneoadjuvantchemotherapy,
with or without radiotherapy). Based on these ﬁndings,
adjuvant trastuzumab therapy has been incorporated into
the standard management of HER2 positive breast cancer
in North America [3–5]. From these studies, the primary
adverse eﬀect of trastuzumab was cardiac toxicity with
impairment of left ventricular ejection fraction. Other
commonly reported toxicities include ﬂu-like symptoms
and cough, abdominal discomfort and diarrhea, and skin
rash [6]. Belkacemi et al. recently reported concurrent
trastuzumab and radiotherapy resulted in 51% grade ≥ 2
acute radiation dermatitis in a French multicentred study,
which is a higher incidence than seen with adjuvant radio-
therapy alone [7]. However, there have been no previous
cases of trastuzumab-associated radiation recall reactions.
Based on previous reviews on radiation recall dermatitis,
this case presentation is consistent with a radiation recall
dermatitis associated with trastuzumab.
Radiation recall dermatitis is a rare complication associ-
ated with exposure to a recall-triggering drug after radiation
treatment, which is poorly understood. In order for the
acute reaction to be classiﬁed as a radiation-recall reaction,
the recall-triggering drug should be given at least 7 days
after radiotherapy. Otherwise, the reaction may be due to
a radiosensitization eﬀect, as the drug interferes with the
cellular repair mechanisms at work after radiation exposure.
In a recent review of the published case reports on radiation
recall dermatitis, the median interval between radiation and
the recall-triggering drug was found to be 39.5 days. In
the same review, the median speed of onset of the recall
reaction was 3 days for intravenous drugs, and the time
taken for resolution of the reaction ranged from hours to
14 days [8]. The primary eﬀective treatment for radiation
recall dermatitis was discontinuation of the drug. All other
attempted treatments, including topical/oral steroids or
antihistamines, have not demonstrated any eﬀect on theCase Reports in Medicine 3
resolution of the reaction. When patients were rechallenged
with the recall-triggering drug, the recall dermatitis did
not consistently recur. Based on the clinical presentation
of radiation recall dermatitis with a rapid onset, rare
incidence, and unpredictable eﬀect of drug rechallenge, the
most plausible possible mechanism is an idiosyncratic drug
hypersensitivity reaction, rather than any cytotoxic eﬀect of
the drug that triggered the reaction [9]. In further support
of this mechanism, there have been a wide range of drugs
associated with radiation recall dermatitis from the most
common being adriamycin and paclitaxel to the very rarely
associated drugs such as TB medications and Tamoxifen
[10–14] .T h en e wt a r g e t e dt h e r a p i e ss u c ha sc e t u x i m a b ,a
monoclonal antibody to epidermal growth factor receptor,
have only been associated with acneiform skin rash until
recent reports of radiation recall phenomenon and increased
radiation dermatitis [15, 16].
This case presents with a very typical presentation of
radiation recall dermatitis following a dose of trastuzumab,
which has not previously been associated with radiation
recall. The clinical distribution of the skin reaction following
the geometrical borders of the radiation ﬁeld, the time to
onset of 3 days, and the time to spontaneous resolution of
14 days are all consistent with previous reports of radiation
recall dermatitis. There are several additional interesting
facets to this case, which pose further questions and pos-
sible mechanisms for radiation recall reactions. This lady’s
documented history of skin hypersensitivity to numerous
allergens including latex raises the question of whether
this may predispose a person to developing radiation recall
dermatitis. Secondly, as the recall dermatitis only developed
after she received her trastuzumab infusion in the ipsilateral
arm to which she received radiotherapy, there may be a dose-
dependent response and a possible threshold dose exposure
that triggers a radiation recall reaction. Similar to previous
cases, this lady was able to complete the remainder of
her planned trastuzumab treatment without another recall
reaction,althougharechallengeintheipsilateralarmwasnot
attempted.
Clearly, the mechanism and etiology of radiation recall
dermatitis remain unclear. The rarity of these reactions
and the heterogeneous presentations of cases add to the
challenges in further characterizing and understanding this
phenomenon.
3. Consent
Informed consent was obtained from the patient for publica-
tion of this case report.
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